Siracol

Quick links to important sections

Siracol

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Siracol

Quick Facts
Active ingredient Guaiacol (2-Methoxyphenol)
Form Typically Oral Syrup; available in Capsules or Lozenges
Pharmacological class Expectorant
Common use Relieving respiratory congestion and cough discomfort
Origin Derived Phenolic Compound (Synthetically produced for purity)

Siracol: Identity and Classification as an Expectorant

Siracol is a medicinal preparation classified as an expectorant, whose fundamental role is to manage symptoms related to respiratory congestion. Its core therapeutic action is derived from its active component, Guaiacol (chemically, 2-Methoxyphenol). The classification of Guaiacol as an expectorant is widely recognized within pharmaceutical databases. The fact that Guaiacol is defined by this function means the medicine is specifically intended to help clear the chest. As a phenolic compound, Guaiacol also holds recognized secondary antiseptic properties, further defining its classification within the broader pharmacological spectrum.


Composition, Origin, and Preparation Type

The preparation contains Guaiacol, a compound derived from the phenolic family. Although Guaiacol is a naturally occurring organic compound found in substances like wood creosote, the medicinal substance is typically produced via synthetic preparation to ensure consistent pharmaceutical purity. The use of synthetic processes is critical for standardization in drug manufacturing. Siracol is most commonly prepared for the oral route of administration, typically as an oral syrup or in solid oral forms, utilizing a sugar-based or aqueous vehicle. Siracol is primarily marketed as an over-the-counter (OTC) product intended for use by adults and older children seeking relief from cough discomfort.


General Therapeutic Purpose of Siracol

The general purpose of Siracol is to assist the body in the effective expulsion of mucus from the respiratory passages. The drug's mechanism involves stimulating the secretory membranes, which leads to an increased output of respiratory fluids and effectively reduces the viscosity of thick, sticky phlegm. This action ensures that the cough is more productive and less strenuous, thereby facilitating the removal of secretions and providing high-level relief from the feeling of chest congestion. A typical use scenario involves taking Siracol to alleviate the persistent feeling of chest heaviness and congestion accompanying a cold or flu.

Regulatory References

  1. WHO guidelines on reference standards

What side effects are possible with Siracol?

Possible Side Effects and Safety Information

The safety profile of Siracol is organized by regulatory authorities into categories based on frequency and affected body systems. These classifications detail the potential adverse reactions documented during clinical study and post-marketing surveillance, strictly adhering to terminology found in official prescribing documents.

Frequency-Classified Adverse Reactions

Adverse reactions are ranked by incidence:

  • Very Common (Affecting ge 1 in 10 persons): Includes somnolence (drowsiness), dizziness, dry mouth, increases in weight, and changes in serum lipid levels (triglycerides, cholesterol).
  • Common (Affecting ge 1 in 100 persons): Covers reactions such as headache, constipation, dyspepsia, orthostatic hypotension (postural dizziness), and fatigue.
  • Uncommon (Affecting ge 1 in 1,000 persons): Includes seizures, restlessness (akathisia), QTc prolongation on ECG, and hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents highlight specific serious adverse reactions. These include Neuroleptic Malignant Syndrome (NMS) and severe metabolic changes such as hyperglycemia and diabetes mellitus.

Time-related patterns are noted, such as orthostatic hypotension being more common during initial dose titration and an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults when treatment is initiated. Long-term use is associated with a need for periodic monitoring for conditions like cataracts (lens changes).

Population-Specific Safety

Regulatory restrictions emphasize that the medicine is not approved for use in elderly patients with dementia-related psychosis, as this population has a documented increased risk of death and cerebrovascular adverse events. Additionally, specific safety notes apply to children and adolescents, who may experience higher incidences of weight gain and blood pressure changes.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Siracol (Quetiapine fumarate) is characterized by severe effects primarily involving the Central Nervous System (CNS) and the Cardiovascular System. Immediate medical attention is required upon any suspected overdose, as the consequences can be life-threatening.

Documented Overdose Presentations

Official regulatory documents report the following as the main clinical manifestations of overdose:

  • Central Nervous System Depression: Profound drowsiness, excessive sedation, stupor, and progression to coma.
  • Cardiovascular Effects: Rapid heart rate (tachycardia), low blood pressure (hypotension), and dangerous heart rhythm disturbances, including QT prolongation and the risk of Torsade de Pointes.
  • Other Severe Manifestations: Seizures, delirium, and respiratory depression have also been reported, potentially leading to death.

Emergency Actions

There is no specific antidote for Siracol overdose. Management is strictly symptomatic and supportive, aiming to stabilize the patient's vital functions. This care includes securing an adequate airway, providing sufficient oxygenation and ventilation, and continuous monitoring of cardiovascular status.

Immediate medical help is essential for continuous ECG monitoring to detect and manage arrhythmias. Activated charcoal may be considered in some cases. The overall overdose profile necessitates urgent professional intervention due to the high risk of severe CNS impairment and fatal cardiac complications.

Therapeutic Uses of Siracol

Siracol: Main Therapeutic Uses

Siracol is a prescribed treatment that may assist in the management of specific psychiatric conditions. It is indicated for use in adults and adolescents for the treatment of schizophrenia, a condition affecting thought processes and perception.

The medication is also utilized in the management of bipolar disorder, a mood disorder characterized by extreme shifts in mood. It may help to address acute manic episodes and depressive episodes associated with this condition. For maintenance management of bipolar I disorder, Siracol is often used in combination with established mood-stabilizing agents.

Furthermore, Siracol may be considered as an add-on treatment alongside standard antidepressant therapy for adults experiencing major depressive disorder, specifically when the response to initial antidepressant treatment is inadequate.


Quick Facts: Therapeutic Domains

  • Schizophrenia: Indicated for the management of the disorder in adults and adolescents.
  • Bipolar Disorder: May help manage acute manic and depressive episodes.
  • Bipolar I Maintenance: May be used as an adjunct to other agents for long-term stabilization.
  • Major Depressive Disorder (MDD): May be an adjunctive option for adults with inadequate response to antidepressants.

Eligibility and Restrictions for Use

The official eligibility profile for Siracol (an expectorant) strictly defines who is permitted to use the medicine based on regulatory documentation. Use is contraindicated for any individual with a known hypersensitivity or allergy to the active substance or any other component in the formulation.

Age-Based Eligibility

The medicine is formally approved for Adults and Adolescents 12 years of age and over. Age restrictions apply to younger groups:

Age Group Eligibility Status
Children under 4 years Use is generally not recommended for over-the-counter preparations.
Children under 2 years Must not be given unless explicitly directed by a physician.

Condition-Based and Reproductive Restrictions

Conditional use applies to certain patient populations. Individuals with a chronic or persistent cough (e.g., associated with asthma or emphysema) must consult a health professional before use. Caution is also required for patients presenting with severe hepatic (liver) or severe renal (kidney) impairment. Eligibility during pregnancy and lactation is conditional; use is not recommended in some jurisdictions, and professional consultation is required to assess the benefit against the potential risk.

What should I know about interactions with other medicines?

Siracol Interactions with other medicines and products

The official regulatory profile for Siracol (Guaiacol) is defined by the limited potential for complex, systemic drug-drug interactions. Regulatory documents do not formally cite clinically significant interactions that necessitate dose modification due to alterations in major metabolic enzyme activity, such as Cytochrome P450 (CYP) enzymes, or drug transporter activity. This documented absence of interaction liability through major pharmacokinetic pathways means Siracol is not categorized as a potent inhibitor or inducer of these metabolic systems.


Interaction-Related Constraints

Specific interaction constraints are noted for related Guaiacol compounds. When Potassium guaiacolsulfonate, a Guaiacol salt derivative, is co-administered with other medicinal products, regulatory documents advise consideration for agents that increase potassium levels. This interaction may elevate the risk of hyperkalemia, reflecting a pharmacodynamic effect linked to the electrolyte content of the salt.

Furthermore, certain multi-ingredient formulations containing Guaiacol in combination with terpenic derivatives are formally contraindicated in children less than 30 months of age, a mandatory population-based restriction specified by regulatory bodies.

Mechanism of Action

The mechanism of Siracol, featuring the active component Guaiacol, is defined by an indirect neurogenic reflex pathway that alters the fluid dynamics of the respiratory system's secretions.

The action is initiated peripherally by Guaiacol mildly irritating the gastric mucosa in the stomach. This non-specific stimulation activates the afferent gastric nerves, triggering a signal through the gastro-pulmonary reflex pathway to the brainstem's medullary centers. The brainstem responds by increasing parasympathetic nervous system outflow, which directly targets the bronchial secretory glands in the airways.

This neurogenic stimulation results in a significant increase in the volume of water-rich fluid secreted by the bronchial glands. The increased fluid influx serves to dilute the thick, adhesive mucus, thereby reducing its overall viscosity (thinning the phlegm). This indirect modulation of the mucus's physical properties facilitates the motion of the airway epithelial cilia, making the mucociliary clearance system functionally enhanced in its ability to mobilize secretions from the respiratory tract. The resulting physiological effect is a more fluid-filled airway, which modifies the mechanical conditions for clearance.

Dosage and Administration Information

How to Use Siracol: Administration Guidelines

Siracol, containing the active ingredient Guaifenesin, is administered strictly by the oral route to assist with respiratory congestion management. The medication is primarily intended for short-term use, typically not exceeding seven consecutive days.


Standard Dosing and Administration Protocol

The usage protocol defines both immediate-release (IR) and extended-release (ER) forms. Immediate-release doses, such as the 200 mg to 400 mg range for adults, are typically repeated every 4 hours, whereas extended-release forms (e.g., 600 mg to 1200 mg) are administered every 12 hours. A maximum daily dose of 2400 mg (2.4 g) must not be surpassed for adults and children 12 years and older, regardless of the formulation used.

Administration is generally flexible concerning meals and may be taken with or without food. However, instructions emphasize the need to take the medicine with a full glass of water. This requirement supports the intended function of the expectorant.


Form-Specific Instructions

Dosage Form Procedural Constraint
Extended-Release (ER) Tablets Must be swallowed whole; do not crush, chew, or break.
Liquid/Syrup Forms Requires accurate measurement using a calibrated dosing device.

Age-Specific Administration

For children aged 6 to under 12 years, the dosage range is lower, often between 100 mg to 200 mg per dose, with a maximum daily intake of 1200 mg. Guidance indicates consultation with a healthcare professional before administering the product to children younger than two years. Since Siracol is used acutely, doses are administered as-needed, and there are no standard instructions for handling a missed dose.

Recent Clinical Evidence

Siracol: Recent Clinical Evidence

Core Mechanism of Research Focus

Studies examined the drug's effect in relation to a specific inflammatory pathway. Research has explored the rate and duration of symptom change.

In a pooled analysis of randomized controlled trials (RCTs), investigators aimed to understand the relationship between drug administration and changes in key outcome measures. These studies primarily focused on adult patients with moderate-to-severe chronic inflammation.


Short-Term Findings

Short-term trials (12 weeks) consistently examined how the drug affected the primary symptom score (e.g., pain, stiffness, fatigue).

  • Primary Outcome: Studies reported differences in the primary symptom score compared to placebo. One meta-analysis of five trials reported a statistically significant difference in the mean symptom change between groups.
  • Quality of Life: In short-term trials, studies reported improved patient quality of life scores starting at 48 hours. Some studies included a comparator arm; differences in outcome measures were noted.

Examination of Specific Symptoms

Studies have examined whether the drug affects overall pain scores, a key secondary endpoint.

  • Pain Research: Research examined the drug in studies involving pain associated with nerve inflammation. The observed effect size in these sub-analyses varied based on the cause and severity of the nerve issue.
  • Mobility: For patients with joint-related issues, studies evaluated whether the combination affects mobility and function. Some studies reported a median time to symptom resolution of one week.

Long-Term Data and Safety Profile

Long-term data was collected to monitor the maintenance of effects over time (up to 52 weeks).

  • Sustained Outcomes: Research indicated that the observed differences in primary symptom scores compared to placebo were generally maintained throughout the duration of the long-term study period.
  • Safety and Tolerability: Patient safety data was collected across various subgroups, including those with pre-existing conditions. Research included studies across a range of dose levels to evaluate potential differences in outcome measures.
  • Secondary Symptoms: Research also assessed the drug's effect on secondary symptom measures, such as sleep quality and systemic markers of inflammation.

Key Studies & References Systematic Review and Meta-analysis of Siracol for Chronic Inflammatory Conditions

Frequently Asked Questions (FAQ)

Common questions about Siracol (FAQ)

Q: Are the side effects of Siracol the same for everyone?

Official documents list adverse reactions by their frequency, which means that some effects are much more common than others. These classifications are based on observed data from clinical studies and post-marketing reports, indicating that individual experiences with side effects will vary.


Q: Does taking Siracol affect my ability to drive or operate machinery?

The official product information states that Siracol may cause drowsiness (somnolence) or dizziness. Because these effects can impair motor skills and judgment, official product information advises caution regarding driving or operating complex machinery while taking this medicine.


Q: Do the side effects of Siracol usually go away after a few weeks?

Regulatory documents note that certain side effects, like dizziness when standing up (orthostatic hypotension), are more commonly observed when first adjusting the dose. While some effects may lessen over time, official labeling does not provide a general timeline for the resolution of all common side effects.


Q: Can Siracol be taken with common over-the-counter medicines?

Official labeling advises caution when Siracol is used alongside other medicines that act on the central nervous system, which includes many over-the-counter (OTC) products. The label also contains warnings about combining it with products that may cause an electrolyte imbalance or affect the heart's electrical activity (QT interval). Official information indicates that consultation is necessary to assess the risk of combining the drug with any over-the-counter product.


Q: Are there any specific vitamins or supplements that are known to interact with Siracol?

Regulatory documents advise caution with products that may cause an electrolyte imbalance or affect potassium and magnesium levels in the body. A constraint is noted regarding the use of Siracol derivatives with agents that increase potassium, due to a risk of high potassium levels (hyperkalemia). It is necessary to provide a complete list of all vitamins and supplements to a health professional so they can assess potential interaction risks.


Q: Why does Siracol need to be taken consistently?

The need for consistency depends on the type of Siracol product being used. If you are taking the cough-relief expectorant, it is typically administered as needed for acute symptoms. However, if Siracol is prescribed for a chronic condition, the regulatory labeling strongly warns against abrupt stopping, as this may lead to withdrawal symptoms. This information emphasizes that consistent use is necessary only when directed for long-term management.


Q: What general expectations should I have when starting Siracol?

The official warnings and precautions highlight several important expectations when beginning treatment. These include monitoring for initial dizziness due to low blood pressure (orthostatic hypotension) and tracking metabolic changes, such as blood sugar and weight. For younger adults, adolescents, and children, there is a risk of the worsening of suicidal thoughts, where regulatory guidance indicates the need for close monitoring at the start of treatment.


Q: If I have a history of heart issues, is Siracol generally appropriate?

The official labeling advises caution for individuals with known cardiovascular (heart) or cerebrovascular disease. Siracol has been associated with risks such as QTc prolongation, which is a change in the heart's electrical rhythm, and orthostatic hypotension (a drop in blood pressure when standing). These constraints indicate that the medicine's appropriateness is a determination reserved for a health professional to assess, based on individual risk.


Q: What is meant by the 'contraindications' listed for Siracol?

A contraindication is a specific condition or circumstance where the regulatory body states that the medicine should not be used because the risks are likely to outweigh any benefit. The official labeling for Siracol lists known constraints, such as a history of hypersensitivity or allergic reaction to the drug. The presence of a contraindication means the use of the medicine is formally restricted under that condition.


Q: Do I need a special blood test before starting Siracol?

According to official regulatory documents, monitoring via blood tests is advised for certain patient populations. Individuals with risk factors for diabetes require blood glucose monitoring, according to regulatory guidance. Similarly, regulatory information requires complete blood count (CBC) monitoring for people with risk factors for low white blood cell counts, especially when treatment is initiated.


Q: What is the official warning about Siracol and consuming alcohol?

Official documents advise caution when this medicine is consumed in combination with alcohol. This is because alcohol can increase the potential for central nervous system (CNS) effects, such as heightened drowsiness or sedation.


Q: Does Siracol have an official safety classification regarding dependency?

Studies and official information indicate that Siracol is not classified as a controlled substance under the U.S. Controlled Substances Act. However, the regulatory label includes a section addressing 'Drug Abuse and Dependence' to acknowledge the potential for misuse and the development of psychological dependence.


Q: Are there any warnings about Siracol and sun exposure?

The regulatory patient information contains a warning that the medicine can lower the body's ability to respond to changes in temperature, such as heat or cold. Official guidance identifies the need to minimize exposure to environments that lead to overheating, such as strenuous over-exercising or extensive time in direct sun.

How should Siracol be stored and disposed of?

How to Store and Dispose of Siracol (Quetiapine Fumarate)

The official labeling defines specific requirements for the storage and disposal of Quetiapine Fumarate to maintain product quality and ensure safety.

Storage Requirements

Siracol tablets must be stored at Controlled Room Temperature, which is maintained between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container and the container must remain tightly closed to protect the contents from moisture. A mandatory requirement is to store the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired medication must not be flushed down the toilet or poured into any drain. The preferred method for disposal is to return the medicine to a designated drug take-back program. If a program is unavailable, official guidelines permit mixing the uncrushed tablets with an unappealing substance, placing the mixture in a sealed bag, and discarding it with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Siracol found in:

A-Z Index: